<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="73170"><DrugName>repurposed lenabasum (cystic fibrosis/scleroderma/systemic lupus erythematosus/dermatomyositis), Corbus Pharmaceuticals</DrugName><DrugNamesKey><Name id="43056273">Resunab</Name><Name id="43114011">lenabasum</Name></DrugNamesKey><DrugSynonyms><Name><Value>ajulemic acid</Value></Name><Name><Value>CT 3</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IP-751</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>repurposed ajulemic acid (cystic fibrosis/scleroderma/systemic lupus erythematosus/dermatomyositis), Corbus Pharmaceuticals</Value></Name><Name><Value>Resunab</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>JBT-101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lenabasum</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>anabasum</Value></Name><Name><Value>CPL-7075</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>repurposed lenabasum (cystic fibrosis/scleroderma/systemic lupus erythematosus/dermatomyositis), Corbus Pharmaceuticals</Value></Name><Name><Value>137945-48-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1063267">JB Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1063267">JB Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1063267" type="Company"><TargetEntity id="5036215909" type="organizationId">Corbus Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1096830" type="Company"><TargetEntity id="5040943458" type="organizationId">Corbus Pharmaceuticals Holdings Inc</TargetEntity></SourceEntity><SourceEntity id="17633" type="Company"><TargetEntity id="4295878524" type="organizationId">Kaken Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1105" type="ciIndication"><TargetEntity id="10039710" type="MEDDRA"></TargetEntity><TargetEntity id="732" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2475" type="ciIndication"><TargetEntity id="M33" type="ICD10"></TargetEntity><TargetEntity id="10012503" type="MEDDRA"></TargetEntity><TargetEntity id="D003882" type="MeSH"></TargetEntity><TargetEntity id="221" type="ORPHANET"></TargetEntity><TargetEntity id="-990050583" type="omicsDisease"></TargetEntity><TargetEntity id="139" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="318" type="ciIndication"><TargetEntity id="M32" type="ICD10"></TargetEntity><TargetEntity id="10042945" type="MEDDRA"></TargetEntity><TargetEntity id="D008180" type="MeSH"></TargetEntity><TargetEntity id="-1461472531" type="omicsDisease"></TargetEntity><TargetEntity id="731" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"></TargetEntity><TargetEntity id="10011762" type="MEDDRA"></TargetEntity><TargetEntity id="D003550" type="MeSH"></TargetEntity><TargetEntity id="586" type="ORPHANET"></TargetEntity><TargetEntity id="-1447400656" type="omicsDisease"></TargetEntity><TargetEntity id="288" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="2581" type="Action"><TargetEntity id="107" type="Mechanism">Cannabinoid CB2 Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00279" type="ciTarget"><TargetEntity id="162460901912693" type="siTarget">Cannabinoid receptor 2</TargetEntity><TargetEntity id="1599581128" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1105">Scleroderma</Indication><Indication id="2475">Dermatomyositis</Indication><Indication id="318">Systemic lupus erythematosus</Indication><Indication id="88">Cystic fibrosis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1295">Neuropathic pain</Indication><Indication id="245">Osteoarthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="2581">Cannabinoid CB2 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="664">Fibrosuppressant</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-29T07:19:58.000Z</LastModificationDate><ChangeDateLast>2019-06-24T00:00:00.000Z</ChangeDateLast><AddedDate>2011-08-25T10:07:36.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1096830" linkType="Company"&gt;Corbus Pharmaceuticals Holdings&lt;/ulink&gt;, following the acquisition of &lt;ulink linkID="1063267" linkType="Company"&gt;JB Therapeutics&lt;/ulink&gt;, is developing  an ultrapure version of a repurposed formulation of  lenabasum (ajulemic acid, JBT-101, Resunab, anabasum),   a non-psychotropic CB2 agonist with anti-inflammatory and anti-fibrotic activities, for the potential oral treatment of  cystic fibrosis (CF), scleroderma,  systemic lupus erythematosus (SLE) and  other chronic inflammatory-fibrotic diseases [&lt;ulink linkID="1217452" linkType="Reference"&gt;1217452&lt;/ulink&gt;], [&lt;ulink linkID="1537449" linkType="Reference"&gt;1537449&lt;/ulink&gt;], [&lt;ulink linkID="1565467" linkType="Reference"&gt;1565467&lt;/ulink&gt;],  [&lt;ulink linkID="1639812" linkType="Reference"&gt;1639812&lt;/ulink&gt;], [&lt;ulink linkID="1646708" linkType="Reference"&gt;1646708&lt;/ulink&gt;], [&lt;ulink linkID="1667144" linkType="Reference"&gt;1667144&lt;/ulink&gt;], [&lt;ulink linkID="1659540" linkType="Reference"&gt;1659540&lt;/ulink&gt;], [&lt;ulink linkID="1912949" linkType="Reference"&gt;1912949&lt;/ulink&gt;], [&lt;ulink linkID="1913082" linkType="Reference"&gt;1913082&lt;/ulink&gt;]. In December 2017, a phase III trial was initiated in patients with systemic sclerosis  [&lt;ulink linkID="1991784" linkType="Reference"&gt;1991784&lt;/ulink&gt;].  In May 2015, a phase II study was  initiated  in patients with dermatomyositis in the US [&lt;ulink linkID="1677270" linkType="Reference"&gt;1677270&lt;/ulink&gt;],  [&lt;ulink linkID="1677167" linkType="Reference"&gt;1677167&lt;/ulink&gt;]; in October 2017, positive top-line results from the trial were reported [&lt;ulink linkID="1972839" linkType="Reference"&gt;1972839&lt;/ulink&gt;]; in September 2018, a phase III trial in dermatomyositis was expected at the end of 2018 [&lt;ulink linkID="2074846" linkType="Reference"&gt;2074846&lt;/ulink&gt;].  In September 2015, a phase II CF trial was initiated  [&lt;ulink linkID="1696472" linkType="Reference"&gt;1696472&lt;/ulink&gt;]; in March 2017, positive topline data  from the  study were reported   [&lt;ulink linkID="1912949" linkType="Reference"&gt;1912949&lt;/ulink&gt;]. In December 2017, an investigator-led, phase II trial for SLE was   initiated [&lt;ulink linkID="1993604" linkType="Reference"&gt;1993604&lt;/ulink&gt;]. In January 2018, a multi-national, FDA-designed, phase IIb trial in CF patients was planned to start in the first quarter of 2018 [&lt;ulink linkID="2000772" linkType="Reference"&gt;2000772&lt;/ulink&gt;], [&lt;ulink linkID="2001133" linkType="Reference"&gt;2001133&lt;/ulink&gt;].    In December 2017,  the company was planning to file an NDA to the US FDA by mid-2020 [&lt;ulink linkID="1991784" linkType="Reference"&gt;1991784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="17633" linkType="Company"&gt;Kaken&lt;/ulink&gt; is investigating the agent for systemic sclerosis  and dermatomyositisÂ in Japan [&lt;ulink linkID="2108393" linkType="Reference"&gt;2108393&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company was previously developing lenabasum, a non-psychotropic CB2 agonist for the potential oral treatment of pain including neuropathic pain and osteoarthritis [&lt;ulink linkID="1217452" linkType="Reference"&gt;1217452&lt;/ulink&gt;]. in February 2013, the drug was still listed as being in phase II development [&lt;ulink linkID="1382585" linkType="Reference"&gt;1382585&lt;/ulink&gt;]; however, in March 2014, pain and osteoarthritis were no longer listed on the company's pipeline as under development  [&lt;ulink linkID="1537449" linkType="Reference"&gt;1537449&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In April 2017, the US approval for scleroderma was expected in the second half of 2020 [&lt;ulink linkID="1916029" linkType="Reference"&gt;1916029&lt;/ulink&gt;]. In December 2017,  the company was planning to file an NDA with the US FDA by mid-2020 [&lt;ulink linkID="1991784" linkType="Reference"&gt;1991784&lt;/ulink&gt;]. In March 2019, the US FDA approval and   launch for scleroderma  was expected in 2021 [&lt;ulink linkID="2129282" linkType="Reference"&gt;2129282&lt;/ulink&gt;].Â &lt;/para&gt;&lt;para&gt;By March 2017, the company had filed for Breakthrough therapy designation with the FDA for lenabasum for the treatment of systemic sclerosis [&lt;ulink linkID="1907323" linkType="Reference"&gt;1907323&lt;/ulink&gt;]. By May 2017, the company had not been granted Breakthrough therapy designation for the treatment of systemic sclerosis [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, the US FDA granted Fast Track Designation to Resunab for the treatment of systemic sclerosis [&lt;ulink linkID="1687657" linkType="Reference"&gt;1687657&lt;/ulink&gt;]. In October 2015, the US FDA granted Fast Track Designation to Resunab for the treatment of CF [&lt;ulink linkID="1705091" linkType="Reference"&gt;1705091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, the company planned to file an Orphan Drug designation application with the FDA during the first quarter of 2015 [&lt;ulink linkID="1611988" linkType="Reference"&gt;1611988&lt;/ulink&gt;]. In May 2015, the company planned to file for Orphan Drug designation  with the US FDA for CF and scleroderma, in the third quarter of 2015 [&lt;ulink linkID="1659540" linkType="Reference"&gt;1659540&lt;/ulink&gt;]. In June 2015, the US FDA granted Orphan Drug designation to lenabasum  for the treatment of systemic sclerosis [&lt;ulink linkID="1669828" linkType="Reference"&gt;1669828&lt;/ulink&gt;], [&lt;ulink linkID="1673560" linkType="Reference"&gt;1673560&lt;/ulink&gt;]. In October 2015, the US FDA granted Orphan Drug designation  for Resunab for the treatment of CF [&lt;ulink linkID="1705091" linkType="Reference"&gt;1705091&lt;/ulink&gt;].	 In July 2018, the FDA granted Orphan Drug designation to lenabasum for the treatment of dermatomyositis [&lt;ulink linkID="2056083" linkType="Reference"&gt;2056083&lt;/ulink&gt;], [&lt;ulink linkID="2063810" linkType="Reference"&gt;2063810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2015, the company planned to file for Orphan Drug designation  with the EMA for CF and scleroderma, in the third quarter of 2015 [&lt;ulink linkID="1659540" linkType="Reference"&gt;1659540&lt;/ulink&gt;]. In August 2015, the company planned to file for European Orphan Drug designation for scleroderma in the third quarter of 2015 [&lt;ulink linkID="1686221" linkType="Reference"&gt;1686221&lt;/ulink&gt;]. In August 2016, filing was expected by the end of 2016 [&lt;ulink linkID="1788246" linkType="Reference"&gt;1788246&lt;/ulink&gt;]. In September 2016, the COMP recommended granting the Orphan Drug designation for the treatment of CF [&lt;ulink linkID="1798089" linkType="Reference"&gt;1798089&lt;/ulink&gt;]. In October 2016, EMA granted Orphan Drug designation for the treatment of CF [&lt;ulink linkID="1864377" linkType="Reference"&gt;1864377&lt;/ulink&gt;]. In December 2016, the EMA's COMP adopted a positive opinion, recommending Â the drug for designation as an Orphan medicinal product for the treatment of systemic sclerosis [&lt;ulink linkID="1887616" linkType="Reference"&gt;1887616&lt;/ulink&gt;]; in January 2017, the Orphan designation was granted [&lt;ulink linkID="1893058" linkType="Reference"&gt;1893058&lt;/ulink&gt;], [&lt;ulink linkID="1897364" linkType="Reference"&gt;1897364&lt;/ulink&gt;]. In September 2018, the COMP recommended granting the drug Orphan designation for treatment of dermatomyositis [&lt;ulink linkID="2079561" linkType="Reference"&gt;2079561&lt;/ulink&gt;]; in October 2018, the Orphan designation was granted [&lt;ulink linkID="2100439" linkType="Reference"&gt;2100439&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cystic fibrosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By May 2017, an agreement  for  phase IIb protocol design for CF from FDA and EMA had been expected by the company by third quarter of 2017 [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. In June 2017, the trial was to begin in the fourth quarter of 2017 [&lt;ulink linkID="1940945" linkType="Reference"&gt;1940945&lt;/ulink&gt;]. In December 2017, a phase II study (&lt;ulink linkID="330986" linkType="Protocol"&gt;NCT03451045&lt;/ulink&gt;; JBT101-CF-002) trial was initiated in the US and expected to  enroll 415 patients from North America, Europe and Australia. The sole primary endpoint was the event rate of pulmonary exacerbation. At that time, the trial was expected to complete in November 2019  [&lt;ulink linkID="2043325" linkType="Reference"&gt;2043325&lt;/ulink&gt;].  In January 2018, the protocol of the trial was designed in conjunction with the FDA. This multi-national, 6-month, multicenter, double-blinded, randomized, placebo-controlled, phase IIb trial in CF patients (expected n = 415)  aged 12 years and older at increased risk for pulmonary exacerbations and regardless of CFTR mutation, infection, or background medications, was planned to begin enrolling and dosing subjects in three cohorts (lenabasum bid 20 mg, lenabasum bid 5 mg  or bid placebo  for 28 weeks, with 4 weeks follow-up off active treatment) in North America, Europe, Israel and Australia in the first quarter of 2018.  At that time, the trial was expected to complete by the end of 2019  [&lt;ulink linkID="2000772" linkType="Reference"&gt;2000772&lt;/ulink&gt;], [&lt;ulink linkID="2001133" linkType="Reference"&gt;2001133&lt;/ulink&gt;]. In February 2018, the first patient dosing was expected in the first quarter of 2018 [&lt;ulink linkID="2003043" linkType="Reference"&gt;2003043&lt;/ulink&gt;]. In March 2019,  top-line data   were expected  in 2020 [&lt;ulink linkID="2129282" linkType="Reference"&gt;2129282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2015, a phase II protocol for CF had been submitted in the US. At that time, the study was expected to begin that quarter  [&lt;ulink linkID="1661548" linkType="Reference"&gt;1661548&lt;/ulink&gt;]. In May 2015, a phase II trial for CF was  expected to commence in the third quarter of 2015 [&lt;ulink linkID="1660938" linkType="Reference"&gt;1660938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, Corbus was planning to initiate phase IIa studies for cystic fibrosis in 2015 [&lt;ulink linkID="1565418" linkType="Reference"&gt;1565418&lt;/ulink&gt;]. In November 2014, the company planned to submit clinical protocol to the FDA under the Resunab IND for cystic fibrosis during the first quarter of 2015. At that time, the company planned to initiate the phase II trial in cystic fibrosis by mid-2015 [&lt;ulink linkID="1611988" linkType="Reference"&gt;1611988&lt;/ulink&gt;]. In February 2015, the trial was planned to be initiated in the second quarter of 2015 [&lt;ulink linkID="1632812" linkType="Reference"&gt;1632812&lt;/ulink&gt;]. In March 2015, the company planned to submit the phase II protocol in the second quarter of 2015 [&lt;ulink linkID="1639812" linkType="Reference"&gt;1639812&lt;/ulink&gt;]. By May 2015, an IND had been submitted to the US FDA to initiate the trial in 70 CF patients,  in the third quarter of 2015 [&lt;ulink linkID="1659540" linkType="Reference"&gt;1659540&lt;/ulink&gt;]. Later that month, the company received FDA clearance to initiate the multi-center, double-blind, randomized, placebo-controlled, multiple dosed, phase II trial (&lt;ulink linkID="231368" linkType="Protocol"&gt;NCT02465450&lt;/ulink&gt;; JBT101-CF-001) to assess the safety, tolerability, pharmacokinetics and efficacy  of Resunab  in patients with CF (expected n = 70). At that time, the trial was expected to commence in the third quarter of 2015 and was expected to  complete within 18 to 21 months [&lt;ulink linkID="1660938" linkType="Reference"&gt;1660938&lt;/ulink&gt;], [&lt;ulink linkID="1667713" linkType="Reference"&gt;1667713&lt;/ulink&gt;]. In June 2015, the trial was expected to begin in July 2015, and complete in April 2017 [&lt;ulink linkID="1667713" linkType="Reference"&gt;1667713&lt;/ulink&gt;]. In August 2015, the trial was expected to commence in 2015 [&lt;ulink linkID="1687657" linkType="Reference"&gt;1687657&lt;/ulink&gt;]. In September 2015, enrollment was initiated.  At that time, the international study was expected to complete in the fourth quarter of 2016 after which top-line data were expected [&lt;ulink linkID="1696472" linkType="Reference"&gt;1696472&lt;/ulink&gt;]. In October 2015, the first patient was dosed in the trial. At that time, the trial was expected to complete by the end of 2016 [&lt;ulink linkID="1703592" linkType="Reference"&gt;1703592&lt;/ulink&gt;]. In March 2016, topline safety and efficacy dataÂ were expected at the end of 2016 [&lt;ulink linkID="1746878" linkType="Reference"&gt;1746878&lt;/ulink&gt;]. In July 2016, the study was ongoing in the US, Belgium, France, Germany, Italy, Poland and the UK [&lt;ulink linkID="1667713" linkType="Reference"&gt;1667713&lt;/ulink&gt;]. In August 2016, enrollment was expected to be completed in the third quarter of 2016 and dosing for phase II studies was expected to be completed in the fourth quarter of 2016 [&lt;ulink linkID="1788246" linkType="Reference"&gt;1788246&lt;/ulink&gt;]. In September 2016, patient enrollmentÂ  was completed. At that time, top-line resultsÂ from the trial were expected in the first quarter of 2017	 [&lt;ulink linkID="1795471" linkType="Reference"&gt;1795471&lt;/ulink&gt;]. In December  2016, the  phase II trial was completed [&lt;ulink linkID="1888852" linkType="Reference"&gt;1888852&lt;/ulink&gt;]. In March 2017, positive topline data from 85 patients from the 16-week study were reported. The primary objective of the trial was achieved and  demonstrated a safety and tolerability profile. A  dose-dependent reduction in a number of acute pulmonary exacerbationsÂ were observed when  compared to placebo.   The highest dose cohort ofÂ anabasum at 20 mg orally, twice per day  had a 75% reduction in the annualized rate of pulmonary exacerbations requiring iv antibiotics compared to placebo cohort. A consistent reduction in multiple inflammatory cell types in sputum, including total leukocytes, neutrophils, eosinophils, and macrophages and inflammatory mediators, including interleukin-8, neutrophil elastase, and immunoglobulin G, were   reduced in sputum by anabasum in a dose-dependent manner. FEV1 was stable throughout the duration of the trial. Cmax values for anabasum were similar to the Cmax of  previously measured   in healthy human volunteers after similar doses of anabasum  [&lt;ulink linkID="1912949" linkType="Reference"&gt;1912949&lt;/ulink&gt;]. In June 2017, further safety data were presented at the 40th ECFC in Seville, Spain. A total of 12 acute pulmonary exacerbations requiring IV antibiotics (APE) were observed, and the rate of APE/year was 0.46. Respiratory disorders, infections, nervous system disorders and gastrointestinal were the most frequent AEs and were reported by 36, 16, 8 and 8% of patients, respectively [&lt;ulink linkID="1955321" linkType="Reference"&gt;1955321&lt;/ulink&gt;]. In November 2017, further data were presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, IN. The most common AE reported was mild dry mouth (13.1%). During the study period, pulmonary function testing remained stable with mean change in predicted FEV1 from week 1 to 12 was -0.25 and -0.13 % for anabasum and placebo groups, respectively, least square (LS) mean difference was -0.42%.Â Quality of life remained stable as well with mean change in CF Questionnaire-Revised Respiratory Symptoms score from week 1 to week 12 was -3.38 and 0.72% for anabasum and placebo groups, respectively, LS mean difference was -1.86 [&lt;ulink linkID="1985949" linkType="Reference"&gt;1985949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other clinical&lt;/subtitle&gt;In May 2015, the company planned to file for clinical trial authorizations in multiple European countries to test Resunab in  CF starting in the third quarter of 2015 [&lt;ulink linkID="1660938" linkType="Reference"&gt;1660938&lt;/ulink&gt;]; at that time, the company planned to file for an EU Investigational Medicinal Products authorization  with the EMA  in the third quarter of 2015 [&lt;ulink linkID="1659540" linkType="Reference"&gt;1659540&lt;/ulink&gt;]. In November 2015, the company intended to file a European Investigational Medicinal Products authorization in the fourth quarter of 2015 [&lt;ulink linkID="1712382" linkType="Reference"&gt;1712382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Scleroderma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2017, an end of phase II meeting with the FDA was conducted to discuss a proposed 	 trial in systemic sclerosis [&lt;ulink linkID="1907323" linkType="Reference"&gt;1907323&lt;/ulink&gt;]. In April 2017, under the US FDA guidelines an international, double-blinded, randomized, placebo-controlled phase III study to evaluate skin thickening, was to be initiated in adult patients (expected n = 270) with systemic sclerosis. Subjects were randomized to receive anabasum 20 mg bid, anabasum 5 mg bid, or placebo bid twice per day for 52 weeks   [&lt;ulink linkID="1916021" linkType="Reference"&gt;1916021&lt;/ulink&gt;], [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. At that time, the study was expected to enroll its first patient in the fourth quarter of 2017 [&lt;ulink linkID="1916021" linkType="Reference"&gt;1916021&lt;/ulink&gt;]. In May 2017, protocol assistance from EMA on the study design was expected in second quarter of  2017; at that time, the study was to be completed in 2018 and data were expected by the end of 2019 [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. In December 2017, the multicenter phase III  trial (RESOLVE-1) was initiated in patients (expected n = 354) with systemic sclerosis. The study would enroll  subjects  in North America, Europe, Israel, Japan, South Korea  and Australia. At that time,  dosing in the trial was expected to complete  by the end of 2019 [&lt;ulink linkID="1991784" linkType="Reference"&gt;1991784&lt;/ulink&gt;]. In January 2018, the parallel assigned trial (&lt;ulink linkID="325653" linkType="Protocol"&gt;NCT03398837&lt;/ulink&gt;; JBT101-SSc-002) to assess the efficacy and safety of lenabasumÂ in diffuse cutaneous systemic sclerosis (SSc) was expected to complete in March 2020 [&lt;ulink linkID="2003043" linkType="Reference"&gt;2003043&lt;/ulink&gt;], [&lt;ulink linkID="2003087" linkType="Reference"&gt;2003087&lt;/ulink&gt;]. In March 2018, the study was expected to complete and report topline data in H1 2020 [&lt;ulink linkID="2012605" linkType="Reference"&gt;2012605&lt;/ulink&gt;]. By August 2018, the trial was recruiting in Australia, Canada, the Netherlands, and the UK  [&lt;ulink linkID="2003087" linkType="Reference"&gt;2003087&lt;/ulink&gt;]. By September 2018, the trial was recruiting in the US, Germany, Israel, Japan and South Korea as well [&lt;ulink linkID="2003087" linkType="Reference"&gt;2003087&lt;/ulink&gt;]. In March 2019,  top-line data   were expected  in 2020 [&lt;ulink linkID="2129282" linkType="Reference"&gt;2129282&lt;/ulink&gt;]. In April 2019, the company announced the change of primary efficacy endpoint from modified Rodnan Skin core (mRSS) to the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (ACR CRISS) score at Week 52, following a Type C meeting with the US FDA, which stated the limitations of current endpoints for trials in SSc and components of ACR CRISS reflect relevant aspects of SSc. The trial protocol and the first and third secondary efficacy endpoints of changes in HAQ-DI and FVC percent predicted, respectively would remain unchanged, and the change in mRSS would become the second secondary efficacy endpoint. At that time, the trial was expected to complete in  the first half of 2020 [&lt;ulink linkID="2144533" linkType="Reference"&gt;2144533&lt;/ulink&gt;]. In May 2019, enrollment   was completed [&lt;ulink linkID="2148122" linkType="Reference"&gt;2148122&lt;/ulink&gt;]. In May 2019, the trial was expected to complete in the summer 2020 [&lt;ulink linkID="2150481" linkType="Reference"&gt;2150481&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2014, Corbus was planning to initiate phase IIa studies for scleroderma in 2015 [&lt;ulink linkID="1565418" linkType="Reference"&gt;1565418&lt;/ulink&gt;]. In November 2014, the company planned to file an IND with the FDA for scleroderma during the first quarter of 2015. At that time, the company planned to initiate the phase II trial in scleroderma during the first half of 2015 [&lt;ulink linkID="1611988" linkType="Reference"&gt;1611988&lt;/ulink&gt;]. In February 2015, an IND was filed with the FDA. At that time, the trial was planned to be initiated in the second quarter of 2015 [&lt;ulink linkID="1632812" linkType="Reference"&gt;1632812&lt;/ulink&gt;]. In March 2015, the IND was approved by the FDA to initiate the double-blind, randomized, placebo-controlled, multiple dosed trial to assess the safety and tolerability of Resunab in patients (expected n = 36), each be treated daily for a period of three months with a follow-up period of one month. At that time, the trial was expected to be completed in 18 months [&lt;ulink linkID="1639812" linkType="Reference"&gt;1639812&lt;/ulink&gt;]. In June 2015, the phase II trial in diffuse cutaneous systemic sclerosis was expected to begin in 2015 [&lt;ulink linkID="1669828" linkType="Reference"&gt;1669828&lt;/ulink&gt;]; Later that month, a  multicenter trial (&lt;ulink linkID="231517" linkType="Protocol"&gt;NCT02465437&lt;/ulink&gt;; JBT101-SSc-001), was planned to be initiated later that month to assess the  efficacy and pharmacokinetics of lenabasum. At that time, the trial was expected to be completed in April 2017 [&lt;ulink linkID="1670557" linkType="Reference"&gt;1670557&lt;/ulink&gt;]. In August 2015, the trial was expected to begin  in the third quarter of 2015 [&lt;ulink linkID="1686221" linkType="Reference"&gt;1686221&lt;/ulink&gt;]. Later that month, enrollment of the patients was initiated. The study was expected to be completed in 16 months and data were expected at the end of 2016 [&lt;ulink linkID="1690388" linkType="Reference"&gt;1690388&lt;/ulink&gt;]. In September 2015, the study was expected to complete in the fourth quarter of 2016 after which top-line data were expected  [&lt;ulink linkID="1696472" linkType="Reference"&gt;1696472&lt;/ulink&gt;]. In October 2015, first patient was dosed in the US [&lt;ulink linkID="1701298" linkType="Reference"&gt;1701298&lt;/ulink&gt;]. In April 2016, the company received approval for a multi-center, double-blind, randomized, placebo-control, 12-month open-label extension study to evaluate the safety and tolerability of Resunab in patients (expected n = 36) with systemic sclerosis. At that time, top-line results from the study were expected in the fourth quarter of 2016 [&lt;ulink linkID="1750909" linkType="Reference"&gt;1750909&lt;/ulink&gt;]. In June 2016, the last patient was enrolled with a total of  44Â patients enrolled. At that time, Corbus  planned to collect data on safety and efficacy of Resunab in systemic sclerosis in the open-label extension phase of the study [&lt;ulink linkID="1773773" linkType="Reference"&gt;1773773&lt;/ulink&gt;]. In August 2016, open-label extension study was to begin in the third quarter of 2016 and dosing for phase II studies was expected to be completed in the fourth quarter of 2016 [&lt;ulink linkID="1788246" linkType="Reference"&gt;1788246&lt;/ulink&gt;]. In October 2016, the trial was completed in 42 patients  [&lt;ulink linkID="1806947" linkType="Reference"&gt;1806947&lt;/ulink&gt;]. In November 2016, positive top-line results were reported. The drug (n=27) was reported to out-perform placebo (n=15) reaching 33% on  week 16, Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score,  versus 0% for placebo. A CRISS score of more than or equal to 20% (CRISS20) was showed. The difference in CRISS scores between lenabasum and placebo groups over the trial period was significant (p = 0.044). The drug was found to be safe. At that time, subjects were planned to be enrolled in a one- year open label extension to obtain data on long-term safety and durability   [&lt;ulink linkID="1874307" linkType="Reference"&gt;1874307&lt;/ulink&gt;]. In March 2017, data were expected to be presented at the Research and Development Day hosted by Corbus, later that month, in NY. Data from analysis of skin biopsies taken from systemic sclerosis patients before and after 12 weeks of treatment  demonstrated that lenabasum  inhibited gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis,   and increased gene expression in pathways associated with lipid metabolism responsible for resolving inflammation [&lt;ulink linkID="1906961" linkType="Reference"&gt;1906961&lt;/ulink&gt;]. In June 2017, further data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain.   Compared to placebo, anabasum treatment led to greater improvement in Modified Rodnan Skin Score (mRSS; p = 0.085), Health assessment questionnaire disability index, physician global assessment and patient global assessment. At week 12, anabasum-treated patients exhibited greater improvement in functional domains of physical function and social role at than placebo patients (treatment difference = 4.6, p = 0.009; 2.7, p = 0.09, respectively). Serious or severe anabasum-related treatment-emergent adverse events (AEs) were not reported. Dizziness and fatigue were the most common AEs reported  [&lt;ulink linkID="1935727" linkType="Reference"&gt;1935727&lt;/ulink&gt;], [&lt;ulink linkID="1938322" linkType="Reference"&gt;1938322&lt;/ulink&gt;]. In August 2017, further data were presented at the 15th International Workshop on Scleroderma Research in the US. Data demonstrated that the drug showed significant improvement in inflammation (p=0.008) and fibrosis (p=0.049) in patients who were treated with anabasum (n = 21) versus patients treated with placebo (n = 13) [&lt;ulink linkID="1951193" linkType="Reference"&gt;1951193&lt;/ulink&gt;]. Later that month, data from the extension study were expected in the fourth quarter of 2017 [&lt;ulink linkID="1952180" linkType="Reference"&gt;1952180&lt;/ulink&gt;]. In November 2017, 12-month data from the study was expected in mid-2018 [&lt;ulink linkID="1979902" linkType="Reference"&gt;1979902&lt;/ulink&gt;]. In November 2017, further data of scleroderma skin patient-reported outcome (SSPRO) were presented at the 81st ACR Annual Meeting in San Diego, CA. At 12 weeks, anabasum-treated patients had significant improvements in SSPRO compared to placebo-treated patients (least square mean difference of -16.9; p = 0.004). Compared to patients who did not improve, patients who improved at 12 weeks had numerically greater SSPRO scores which was statistically significant for MDGA (p = 0.0146), although not significant for CRISS (p = 0.1856), HAQ-DI (p = 0.4331), or PtGA (p = 0.4639) [&lt;ulink linkID="1978475" linkType="Reference"&gt;1978475&lt;/ulink&gt;]. Further data from open-label extension were presented at the same conference. During open-label treatment period, patients previously treated with anabasum achieved repeated improvement in skin symptoms and Patient's Global Assessment of Disease Activity; and patients who were previously treated with placebo also exhibited new improvement. Low level of SSc skin symptoms with score of &amp;lt;/= 30 points during open-label dosing was achieved by 14/32 patients. At week 28, the median American College of Rheumatology (ACR) CRISS following open-label dosing was 71%. By week 28, ACR CRISS &amp;gt;/= 30, 50, 70 and 90% was achieved by 75, 53, 44 and 36% of patients, respectively [&lt;ulink linkID="1979072" linkType="Reference"&gt;1979072&lt;/ulink&gt;], [&lt;ulink linkID="1978564" linkType="Reference"&gt;1978564&lt;/ulink&gt;]. At the same conference, further clinical data were presented. Anabasum induced clinically relevant molecular responses by modulating inflammatory and fibrotic genes and pathways consistent with the resolution of innate immune signaling. Changes in gene expression in the skin of anabasum-treated subjects were accompanied by improvement in CRISS, mRSS and Scleroderma Disease Severity Score [&lt;ulink linkID="1978464" linkType="Reference"&gt;1978464&lt;/ulink&gt;]. At the same conference, similar data were presented [&lt;ulink linkID="1978426" linkType="Reference"&gt;1978426&lt;/ulink&gt;].    In June 2018, results from the open-label extension (OLE) phase were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Out of 42 patients enrolled, 36 entered the OLE. During the OLE, 91.7% of patients reported &amp;gt;/= 1 AE. In the OLE period, CRISS score improved further in patients who received lenabasum: the proportion of patients attaining CRISS score was 21, 35, 65, 63, 70, 77 and 92% at weeks 4, 12, 20, 28, 36, 44 and 52, respectively. Mean change in mRSS in the lenabasum group at weeks 4, 12, 20, 28, 36, 44 and 52 was -5.3, -6.6, -7.1, -8.4, -7.3, -8.9 and -9.4, respectively [&lt;ulink linkID="2045057" linkType="Reference"&gt;2045057&lt;/ulink&gt;], [&lt;ulink linkID="2045464" linkType="Reference"&gt;2045464&lt;/ulink&gt;]. In October 2018, further open-label extension phase data were presented at the 82nd ACR Annual Meeting in Chicago, IL. The median ACR CRISS reached 99% at 18 months, stable from 95% at 12 months.  As assessed with PtGA and physician global assessment of health (MDGA), overall disease improved, reached a mean of -1.0 and -1.0 in PtGA and MDGA, respectively, at 18 months; improvements observed were durable, with general stability in PtGA and MDGA from months 12 to 18. The mRSS was improved and durable, with mean mRSS score about -10 points from months 12 to 18; 47% of patients achieved a low absolute mRSS of &amp;lt;/=  10 points [&lt;ulink linkID="2084420" linkType="Reference"&gt;2084420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;By August 2011, a single phase II study in chronic refractory neuropathic pain patients had been completed and the results showed  a strong analgesic signal in the primary pain efficacy endpoint and a clinically meaningful benefit of the secondary endpoints [&lt;ulink linkID="1217452" linkType="Reference"&gt;1217452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Dermatomyositis&lt;/subtitle&gt;In February  2018, the company expected to initiate the next phase development for the treatment of skin-predominant dermatomyositis in the second half of 2018 [&lt;ulink linkID="2003043" linkType="Reference"&gt;2003043&lt;/ulink&gt;]; in September 2018, a phase III trial in this setting was expected at the end of 2018 [&lt;ulink linkID="2074846" linkType="Reference"&gt;2074846&lt;/ulink&gt;]. In December 2018, a double-blinded placebo-controlled 1-year phase III trial (NCT03813160; JBT101-DM-002; DETERMINE) was initiated in subjects (expected n = 150) with dermatomyositis to test efficacy and safety of lenabasum. The primary efficacy outcome at week 52 would be total improvement score (TIS), which would be a weighted composite measure of improvement from baseline in six endpoints, including physician global assessment of disease activity, physician global assessment of  extramuscular disease activity, physician global assessment of  disease activity, health assessment questionnaire (patient-reported disability), manual muscle testing, and muscle enzymes [&lt;ulink linkID="2105283" linkType="Reference"&gt;2105283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, a safety, tolerability, efficacy, placebo-controlled phase II study was open for enrollment of patients (expected n = 22) with skin-predominant dermatomyositis, in the US. At that time, the study was expected to complete in âearly 2017â [&lt;ulink linkID="1667144" linkType="Reference"&gt;1667144&lt;/ulink&gt;]; later that month, a double-blind, randomized, placebo-controlled, safety and efficacy phase II trial (&lt;ulink linkID="231808" linkType="Protocol"&gt;NCT02466243&lt;/ulink&gt;; JBT101-DM-001, 116313, R21AR066286) was initiated in patients (expected n = 22) with dermatomyositis, in the US. At that time, the trial was expected to complete in December 2016 [&lt;ulink linkID="1677270" linkType="Reference"&gt;1677270&lt;/ulink&gt;]; in July 2015, the first patient was dosed and the trial was expected to complete in early 2017 [&lt;ulink linkID="1677167" linkType="Reference"&gt;1677167&lt;/ulink&gt;]. In August 2015, data from the trial was expected at the end of 2016 [&lt;ulink linkID="1690388" linkType="Reference"&gt;1690388&lt;/ulink&gt;]. In March 2016, the trial was expected to complete  during the first quarter of 2017 [&lt;ulink linkID="1746878" linkType="Reference"&gt;1746878&lt;/ulink&gt;]. In August 2016, enrollment was expected to be completed in the second quarter of 2017 [&lt;ulink linkID="1788246" linkType="Reference"&gt;1788246&lt;/ulink&gt;]. In September 2016, data from the trial was expected in the second half of 2017 [&lt;ulink linkID="1795471" linkType="Reference"&gt;1795471&lt;/ulink&gt;]. In March 2017, enrolment of patients in the trial was expected to complete in the first quarter of 2017 [&lt;ulink linkID="1907323" linkType="Reference"&gt;1907323&lt;/ulink&gt;]. In May 2017, enrollment was expected to complete in the second quarter of 2017. At that time, top-line data was to be reported in the fourth quarter of 2017 [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. In May 2017, patient enrollment Â was completed. At that time, enrollment was ongoing in the  open-label extension phase II trial [&lt;ulink linkID="1926850" linkType="Reference"&gt;1926850&lt;/ulink&gt;]. In October 2017, positive top-line results from the 16-week trial were reported. Data demonstrated that the mean improvement (reduction) in the primary efficacy outcome, the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score, was 9.3 points for anabasum treatment at the end of the study versus a reduction of 3.7 points for placebo treatment (p = 0.04). Also, anabasum outperformed placebo in multiple secondary efficacy outcomes studied and was well-tolerated [&lt;ulink linkID="1972839" linkType="Reference"&gt;1972839&lt;/ulink&gt;]. In November 2017, further clinical data were presented at the 81st ACR Annual Meeting in San Diego, CA. At the end of study, 56 and 28% of patients had &amp;gt;/= 10 point reduction in CDASI activity score in anabasum versus placebo patients, respectively (p = 0.09). During active dosing, skin erosions were developed in 0 and 36% of patients in anabasum and placebo groups, respectively (p = 0.05) [&lt;ulink linkID="1979065" linkType="Reference"&gt;1979065&lt;/ulink&gt;]. In March 2018, 6-month data from the trial were expected in mid-2018 [&lt;ulink linkID="2012605" linkType="Reference"&gt;2012605&lt;/ulink&gt;]. In May 2018, data were presented at the IID 2018 in Orlando, FL. Compared to placebo, lenabasum provided greater improvement in patient-reported global skin disease and overall disease assessments, skin symptoms including photosensitivity and itch, fatigue, sleep, interference with activities, pain, and physical function. At multiple visits after week 4, improvements in secondary efficacy outcomes reached statistical significance (p &amp;lt;/= 0.1) [&lt;ulink linkID="2103529" linkType="Reference"&gt;2103529&lt;/ulink&gt;]. In June 2018, further data were presented at 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. In Part A and OLE patients, adverse events (AEs) unrelated to study drug reported by 3 and 8 patients, respectively; related to study drug reported by 8 and 5 patients, respectively; mild AEs reported by 7 and 12 patients, respectively; moderate AEs reported by 4 and 5 patients, respectively; and no severe, serious AEs and AEs leading to discontinuation were reported. At week 28, mean improvement in CDASI activity score during OLE was 15.4 points [&lt;ulink linkID="2045211" linkType="Reference"&gt;2045211&lt;/ulink&gt;]. At the same conference, further clinical data were presented. Lenabasum was well-tolerated with a favorable safety profile. Lenabasum demonstrated greater improvement versus placebo in patient- and physician-reported outcomes [&lt;ulink linkID="2045068" linkType="Reference"&gt;2045068&lt;/ulink&gt;]. In October 2018, further data were presented at 82nd ACR Annual Meeting in Chicago, IL. At week 12, significant reduction in CD4+ area (p &amp;lt; 0.05), IFN signature, IFN-beta protein staining, IFN-gamma mRNA and protein staining (p &amp;lt; 0.05 for all) was observed in the lenabasum group compared with the placebo group. There was a reduction in IL-13 protein, which correlated with the change in itch [&lt;ulink linkID="2084324" linkType="Reference"&gt;2084324&lt;/ulink&gt;].  Further data were presented at the same conference. CDASI activity scores improved (decreased) with mean change from baseline to 12 months in CDASI activity score of -17.6 points.  At 12 months, 84% of patients achieved an improvement in CDASI activity score of &amp;gt;/= -10 points (an improvement that exceeded the reported minimal important difference). The improvement in CDASI activity scores was continued at month 12 [&lt;ulink linkID="2084294" linkType="Reference"&gt;2084294&lt;/ulink&gt;]. In May 2019, further data were presented at the 77th Meeting of the Society for Investigative Dermatology in Chicago, IL. The incidence of adverse events (AE) was reported in 65% patients, with 25.0% patients having &amp;gt;/= 1 AE (all mild) related to drug. At week-28, mean changes from baseline in CDASI activity score was -15.4 points, with 82.3 and 47.1% patients achieving &amp;gt;/= 10-point improvement and &amp;lt;/= 14 points, respectively; in 10-cm Physician Overall Disease VAS was -2.6 points, with 82.3 patients achieving &amp;gt;/= 1 point and 20% improvement [&lt;ulink linkID="2163937" linkType="Reference"&gt;2163937&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, the company commenced a one-year, open-label extension study and submitted for review to the FDA [&lt;ulink linkID="1879075" linkType="Reference"&gt;1879075&lt;/ulink&gt;].	&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Systemic lupus erythematosus&lt;/subtitle&gt;In March 2016, the company planned to initiate a phase II trial to evaluate the safety and efficacy of Resunab in adult SLE patients (expected n = 100) with active musculoskeletal disease in the US [&lt;ulink linkID="1740967" linkType="Reference"&gt;1740967&lt;/ulink&gt;]. In March 2016, the trial was expected to launch in the first quarter of 2017 [&lt;ulink linkID="1746878" linkType="Reference"&gt;1746878&lt;/ulink&gt;]. Later that month, a protocol amendment was added to the company's existing IND with the FDA for initiation of the trial [&lt;ulink linkID="1747755" linkType="Reference"&gt;1747755&lt;/ulink&gt;]. In August 2016, the trial was to begin in the first half of 2017 [&lt;ulink linkID="1788246" linkType="Reference"&gt;1788246&lt;/ulink&gt;]. In February 2017, the trial was expected to begin in the first quarter of 2017  [&lt;ulink linkID="1902992" linkType="Reference"&gt;1902992&lt;/ulink&gt;]. In March 2017, the National Institute of Allergy and Infectious Diseases was to begin in collaboration with Corbutus a double-blind, randomized, placebo-controlled, multicenter, phase II study (&lt;ulink linkID="291913" linkType="Protocol"&gt;NCT03093402&lt;/ulink&gt;; DAIT ALE09) to assess the efficacy, safety, and tolerability of lenabasum in systemic lupus erythematosus patients (expected n = 100), in May 2017 in the US. The study was to complete in February 2020 [&lt;ulink linkID="1913082" linkType="Reference"&gt;1913082&lt;/ulink&gt;]. Later that month, the trial was expected to begin in the  second quarter of 2017 [&lt;ulink linkID="1906961" linkType="Reference"&gt;1906961&lt;/ulink&gt;]; later that month, the trial was expected to start during the first half of 2017 [&lt;ulink linkID="1912949" linkType="Reference"&gt;1912949&lt;/ulink&gt;]. By May 2017, the trial had to be evaluated at doses 5 mg, 20 mg, and 20 mg twice daily, for 12 weeks, with 1 month follow-up [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. In August 2017, the trial was expected to begin in the fourth quarter of 2017 [&lt;ulink linkID="1952180" linkType="Reference"&gt;1952180&lt;/ulink&gt;]. In December 2017, the trial was initiated [&lt;ulink linkID="1993604" linkType="Reference"&gt;1993604&lt;/ulink&gt;]. In February 2018, patient dosing was commencedÂ  in the trial [&lt;ulink linkID="2012605" linkType="Reference"&gt;2012605&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I and other clinical&lt;/subtitle&gt;In January 2018, data were published. A total of 22 healthy volunteers were injected with bacteria into the skin to trigger an acute innate immune response and then treated with 5 or 20 mg of oral lenabasum twice a day. Lenabasum was observed to activate resolution of innate immune responses. The drug inhibited neutrophil infiltration and enhanced clearance of bacteria [&lt;ulink linkID="2005641" linkType="Reference"&gt;2005641&lt;/ulink&gt;], [&lt;ulink linkID="2005823" linkType="Reference"&gt;2005823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, data from a placebo-controlled study which evaluated the efficacy of anabasum in healthy subjects were presented at the 81st ACR Annual Meeting in San Diego, CA. Subjects received placebo (n = 5), or anabasum 5 or 20 mg bid (n = 5 each), or prednisolone 15 mg qd (n = 5) for 4 days followed by triggering of acute inflammation by intradermal injection of ultraviolet light-killed Escherichia coli on both forearms. At 4 and 10 h post-challenge with E coli, anabasum 20 mg reduced the accumulation of neutrophils and neutrophil chemokine IL-8 in the blister exudate, equivalent to prednisolone. Both doses of anabasum accelerated bacterial clearance to 4 hours post-challenge. In contrast, prednisolone slowed bacterial clearance during the resolution phase [&lt;ulink linkID="1978407" linkType="Reference"&gt;1978407&lt;/ulink&gt;]. Later that month, similar data were presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, IN [&lt;ulink linkID="1985905" linkType="Reference"&gt;1985905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, data on the effects of Resunab in a model of inflammation in healthy volunteers trial were presented at the 6th European Workshop on Lipid Mediators in Frankfurt, Germany. Data demonstrated that treatment with both 5 on 5 mg Resunab bid and 5 on 20 mg Resunab bid exerted potent anti-inflammatory effects by inhibiting neutrophil infiltration (approximately 70%). The drug correspondingly decreased micro-vascular blood flow around the site of inflammation at 4h post stimulus. Also, the drug progressively increased micro-vascular flow around the site of inflammation during the early phases of resolution, and event believed to drive an efficient acute inflammatory response and signal its timely resolution [&lt;ulink linkID="1802677" linkType="Reference"&gt;1802677&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2014, a phase I safety study in 132 subjects had been completed [&lt;ulink linkID="1537449" linkType="Reference"&gt;1537449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2011, three clinical studies   to establish pharmacokinetics, safety, efficacy and tolerability of lenabasum had been conducted. A  total of 155 patients and healthy volunteers  were treated [&lt;ulink linkID="1217452" linkType="Reference"&gt;1217452&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2017, preclinical data were to be presented at the Research and Development day hosted by Corbus, in March 2017, in NY. In the experiment, the patient's macrophages were stimulated ex-vivo with lipopolysaccharide derived fromÂ Pseudomonas aeruginosa, and cultured with and without lenabasum. Macrophages treated with lenabasum demonstrated a reduced production of two important pro-inflammatory cytokines (tumor necrosis factor alpha and interleukin-6) compared to stimulated macrophages untreated by lenabasum [&lt;ulink linkID="1902992" linkType="Reference"&gt;1902992&lt;/ulink&gt;]. In October 2018, similar data were presented at the 32nd Annual North American Cystic Fibrosis Conference in Denver, CO. In AMs exposed to lenabasum there was reduction in LPS-stimulated XBP-1s and SPHK-1 mRNA levels, coinciding with reduction of LPS-stimulated secretion of TNFalpha &lt;br&gt;&lt;/br&gt;and IL-8. Lenabasum increased secretion of the pro-resolution mediator 15d-PGJ2 [&lt;ulink linkID="2111482" linkType="Reference"&gt;2111482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2015, data from pre-clinical and human ex-vivo modelsÂ demonstrated that the binding of Resunab to CB2 activated the production of specialized pro-resolving lipid mediators (SPMs)Â responsible for inflammation and fibrosis [&lt;ulink linkID="1690388" linkType="Reference"&gt;1690388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, positive preclinical data from a study which determined the effects of  Resunab in  the cystic fibrosis transmembrane conductance regulator (CFTR)-deficient mouse model were presented at the 2015 Cystic Fibrosis Foundation Research Conference in Chantilly, Virginia. Data demonstrated that weight loss was decreased, lung inflammation was resolved, bacterial load was reduced, and survival was improved by  Resunab in a CFTR-deficient mouse model infected with Pseudomonas aeruginosa [&lt;ulink linkID="1665322" linkType="Reference"&gt;1665322&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the Experimental Biology 2015 in Boston, MA in animals with lung fibrosis induced by bleomycin (BLM). Data demonstrated that the drug had significantly decreased fibrotic response and exerted potent anti-fibrotic effects. Additionally marked decrease of TGF-beta and CTGF expression, significant reduction of alpha-SMA positive cells and significant increase of PPAR-gamma expression was observed in AjA groups. AjA exerted potent anti-fibrotic effects in BLM-lung fibrosis also when given during the fibrogenic phase [&lt;ulink linkID="1646708" linkType="Reference"&gt;1646708&lt;/ulink&gt;], [&lt;ulink linkID="1646875" linkType="Reference"&gt;1646875&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2011, data had reported that the drug was effective   in 15 animal models of pain and inflammation and was evaluated in a number of safety pharmacology and toxicology studies  [&lt;ulink linkID="1217452" linkType="Reference"&gt;1217452&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By May 2017, a Pediatric Investigational Plan was planned to be submitted to the EMA soon [&lt;ulink linkID="1925908" linkType="Reference"&gt;1925908&lt;/ulink&gt;]. In August 2017, the company planned to submit a Pediatric Investigational Plan to the EMA [&lt;ulink linkID="1952180" linkType="Reference"&gt;1952180&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-17T00:00:00.000Z</StatusDate><Source id="2105283" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-18T00:00:00.000Z</StatusDate><Source id="2003087" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-17T00:00:00.000Z</StatusDate><Source id="1667713" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-21T00:00:00.000Z</StatusDate><Source id="1696472" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-22T00:00:00.000Z</StatusDate><Source id="1993604" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-03T00:00:00.000Z</StatusDate><Source id="2108393" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-29T00:00:00.000Z</StatusDate><Source id="2000772" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-11T00:00:00.000Z</StatusDate><Source id="2079561" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-29T00:00:00.000Z</StatusDate><Source id="2000772" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-03T00:00:00.000Z</StatusDate><Source id="2108393" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-04T00:00:00.000Z</StatusDate><Source id="1218326" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-08-25T00:00:00.000Z</StatusDate><Source id="1217452" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-21T00:00:00.000Z</StatusDate><Source id="1537449" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-21T00:00:00.000Z</StatusDate><Source id="1537449" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-05T00:00:00.000Z</StatusDate><Source id="1667144" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-23T00:00:00.000Z</StatusDate><Source id="1565467" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-23T00:00:00.000Z</StatusDate><Source id="1565467" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-31T00:00:00.000Z</StatusDate><Source id="1690388" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-07T00:00:00.000Z</StatusDate><Source id="1740967" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-14T00:00:00.000Z</StatusDate><Source id="1991784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-08T00:00:00.000Z</StatusDate><Source id="1677270" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-03T00:00:00.000Z</StatusDate><Source id="1218326" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063267">JB Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-08-24T00:00:00.000Z</StatusDate><Source id="1217452" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="1105">Scleroderma</Indication><AwardedIndication>Treatment of systemic sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</MileStoneDate><Source id="1907323" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of CF</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-20T00:00:00.000Z</MileStoneDate><Source id="1705091" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="1105">Scleroderma</Indication><AwardedIndication>Treatment of systemic sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-19T00:00:00.000Z</MileStoneDate><Source id="1687657" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2475">Dermatomyositis</Indication><AwardedIndication>Treatment of dermatomyositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-26T00:00:00.000Z</MileStoneDate><Source id="2100439" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2475">Dermatomyositis</Indication><AwardedIndication>Treatment of dermatomyositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-13T00:00:00.000Z</MileStoneDate><Source id="2079561" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="2475">Dermatomyositis</Indication><AwardedIndication>Treatment of dermatomyositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-18T00:00:00.000Z</MileStoneDate><Source id="2056083" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1105">Scleroderma</Indication><AwardedIndication>Treatment of systemic sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</MileStoneDate><Source id="1893058" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis (âCFâ)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-18T00:00:00.000Z</MileStoneDate><Source id="1864377" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-14T00:00:00.000Z</MileStoneDate><Source id="1864377" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-08T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="1105">Scleroderma</Indication><AwardedIndication>Treatment of Systemic Sclerosis (Scleroderma)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-12T00:00:00.000Z</MileStoneDate><Source id="1669828" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-13T00:00:00.000Z</MileStoneDate><Source id="1705091" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1096830">Corbus Pharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="1105">Scleroderma</Indication><AwardedIndication>Treatment of systemic sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-10T00:00:00.000Z</MileStoneDate><Source id="1669828" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00279"><Name>Cannabinoid CB2 receptor</Name><SwissprotNumbers><Swissprot>P34972</Swissprot><Swissprot>P47936</Swissprot><Swissprot>Q9QZN9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1096830">Corbus Pharmaceuticals Holdings Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20658">University of Pennsylvania</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCCCC(C)(C)c1cc(c2c(c1)OC([C@H]3[C@H]2CC(=CC3)C(=O)O)(C)C)O</Smiles></StructureSmiles><Deals><Deal id="137353" title="US Government to award JB Therapeutics funding for the development of its JBT-101 and JBT-101SR"></Deal><Deal id="154587" title="CFFT to award Corbus Pharmaceuticals funding for a phase II clinical trial of Resunab against cystic fibrosis   "></Deal><Deal id="155337" title="University of Pennsylvania to conduct phase II trials of Corbus' Resunab against dermatomyositis   "></Deal><Deal id="155344" title="NIAMS to award University of Pennsylvania funding to develop repurposed ajulemic acid for dermatomyositis   "></Deal><Deal id="252569" title="Kaken to develop and commercialize Corbus' Lenabasum  for systemic sclerosis and dermatomyositis in Japan"></Deal></Deals><PatentFamilies><PatentFamily id="2784480" number="WO-2014127016" title="Ultrapure tetrahydrocannabinol-11-oic acids"></PatentFamily><PatentFamily id="3835301" number="WO-2017190070" title="Methods for the treatment of infection"></PatentFamily><PatentFamily id="4479909" number="WO-2019079677" title="Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Corbus Pharmaceuticals Holdings Inc" id="1096830"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>